3-TRENBOMED 150, Deus Medical (Trenbolone Blend)

Deus Medical 3-TRENBOMED 150 is a premium multi-ester injectable anabolic research compound standardized at a total concentration of 150 mg/mL. Packaged in a box of 10 single-dose ampoules (1 mL per ampoule), this formulation combines fast-acting, medium-acting, and long-acting Trenbolone esters to establish a stable, multi-phase pharmacokinetic release profile.

By integrating three esterified variations of 19-norandrostenedione, 3-TRENBOMED 150 eliminates the steep concentration fluctuations associated with single-ester administration in experimental models. Trenbolone exhibits exceptionally strong androgen receptor affinity and anabolic potency without undergoing aromatization into estrogen.

Key Specifications & Active Ingredients

 Total Concentration: 150 mg/mL

 Trenbolone Acetate: 50 mg/mL (Fast-acting short ester)

 Trenbolone Enanthate: 50 mg/mL (Medium-acting long ester)

 Trenbolone Hexahydrobenzylcarbonate: 50 mg/mL (Slow-release long ester)

 Volume: 10 Ampoules x 1 mL

 Manufacturer: Deus Medical

 Formulation: Injectable Solution in Carrier Oil

 Classification: Anabolic-Androgenic Research Compound

Dosage & Research Administration Protocol

 Experimental Standard Dosage: In advanced endocrine and physiological research models, standard protocol ranges evaluate total compound administration between 150 mg and 300 mg per week (1 to 2 mL total volume weekly).

 Administration Frequency: Due to the fast-acting Acetate ester component, doses in multi-phase models are typically divided into twice-weekly intramuscular injections (e.g., 0.5 mL to 1 mL every 3 to 4 days) to maintain steady-state serum concentration.

 Research Model Duration: Typical research observation periods range from 8 to 12 weeks maximum due to compound potency and severe HPTA suppression dynamics.